Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor‐naïve patients with myelofibrosis: Results of a phase II trial

Myelofibrosis (MF) is associated with several constitutional symptoms. Currently, there are few therapeutic options for MF. Jaktinib, a novel, small‐molecule inhibitor of JAK, is currently being studied for its potential to treat MF. This phase 2 trial investigated efficacy and safety of jaktinib in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yi, Zhou, Hu, Jiang, Zhongxing, Wu, Dengshu, Zhuang, Junling, Li, Wei, Jiang, Qian, Wang, Xiuli, Huang, Jinwen, Zhu, Huanling, Yang, Linhua, Du, Xin, Li, Fei, Xia, Ruixiang, Zhang, Feng, Hu, Jianda, Li, Yan, Hu, Yu, Liu, Jing, Jin, Chenghao, Sun, Kai, Zhou, Zeping, Wu, Liqing, Yu, Wenjuan, Jin, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092883/
https://www.ncbi.nlm.nih.gov/pubmed/36054786
http://dx.doi.org/10.1002/ajh.26709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092883/
https://www.ncbi.nlm.nih.gov/pubmed/36054786
http://dx.doi.org/10.1002/ajh.26709

Ejemplares similares